Today

Agents

Chat

Arena

Discover

More

App

Regenxbio Q2 Operating Expenses USD 78.756 Million - RGNX News | Rallies

Regenxbio Q2 Operating Expenses USD 78.756 Million

RGNX•2026-08-06

Q2 operating expenses and revenue

Aug. 6 (Reuters) - Regenxbio Q2 license & royalty revenue was USD 103.841 million.

Q2 operating expenses were USD 78.756 million.
Q2 net income was USD 22.709 million.

Related News

Sabre Q2 FY26 net loss narrows to $36 million; revenue rises 4% to $712 million YoY

SABR•2026-08-06

Onterris: BofA Global Research cuts price objective to $18.00 from $31.00

ONT•2026-08-06

Electra Battery Materials backs US black mass export curbs to bolster domestic refining capacity

ELBM

•

2026-08-06

DoorDash <DASH.O>: Raymond James Raises Target Price to $250 From $225

DASH•2026-08-06

Ingles Markets FY26 Q3 net income slips 1.1% to $25.9 million; net sales rise 1.5% to $1.37 billion

IMKTA•2026-08-06